100 subject matter experts were surveyed from smaller biotech innovators to gain insight into the dynamics and drivers of the current biologics market.
The biologic drugs sector has undergone considerable evolution since the first biologic drug — insulin — was approved by the FDA in 1982. These drugs have revolutionized the treatment of a wide range of diseases, from cancer and autoimmune disorders to genetic disorders and rare diseases. Large molecule drugs, which are typically derived from living cells and are more complex than traditional small molecule drugs, have shown remarkable efficacy and have transformed the lives of millions of patients worldwide.
FILL OUT THE FORM TO DOWNLOAD THE REPORT >>>